2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
39
Leukemia, Myeloid, Acute
35
Myelodysplastic Syndromes
33
Multiple Myeloma
30
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Graft vs Host Disease
26
Leukemia, Lymphocytic, Chronic, B-Cell
25
Lymphoma
24
Leukemia
24
Hematologic Neoplasms
20
Neoplasms
18
Lymphoma, Mantle-Cell
18
Sarcoma
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Breast Neoplasms
17
Tuberous Sclerosis
15
Myeloproliferative Disorders
15
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma, Follicular
14
Burkitt Lymphoma
14
Waldenstrom Macroglobulinemia
13
Lymphoma, B-Cell, Marginal Zone
13
Recurrence
12
Neoplasm Metastasis
12
Carcinoma, Non-Small-Cell Lung
12
Prostatic Neoplasms
11
Primary Myelofibrosis
11
Melanoma
11
Leukemia, Myelomonocytic, Chronic
11
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
trametinib
3
fludarabine
3
dabrafenib
3
Tacrolimus
3
Melphalan
3
Cyclophosphamide
3
Busulfan
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
erdafitinib
2
ensartinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Rituximab
2
Mycophenolic Acid
2
LY3023414
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Sirolimus
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled